Literature DB >> 23428103

Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review.

Matthew E Falagas1, Giannoula S Tansarli, Anastasios Kapaskelis, Konstantinos Z Vardakas.   

Abstract

The authors sought to evaluate the impact of ertapenem use on the resistance of Gram-negative bacteria (in general and in specific species) to group 2 carbapenems. PubMed and Scopus databases were systematically searched. Eight studies were included; all reported on Pseudomonas aeruginosa and four reported on Enterobacteriaceae. Five studies did not show any difference in group 2 carbapenem resistance for P. aeruginosa, while three reported a significant decline after ertapenem introduction. Three studies did not show any difference in group 2 carbapenem resistance between the compared periods for Enterobacteriaceae and one study did not present a statistical analysis. In conclusion, the currently available data suggest that ertapenem use does not affect the resistance of Gram-negative bacteria to group 2 carbapenems.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428103     DOI: 10.1586/eri.12.149

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  7 in total

1.  Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing Enterobacterales Bacteremia Receiving Ertapenem versus Other Carbapenems.

Authors:  Jin Ju Park; Eun-Ju Jung; Jae-Young Kim; Yu Bin Seo; Jacob Lee; Younghee Jung
Journal:  Antimicrob Agents Chemother       Date:  2022-06-16       Impact factor: 5.938

2.  Safety and efficacy of long-term outpatient ertapenem therapy.

Authors:  Zubair A Qureshi; Alveena Syed; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

3.  Stepwise Expansion of Antimicrobial Stewardship Programs and Its Impact on Antibiotic Use and Resistance Rates at a Tertiary Care Hospital in Korea.

Authors:  Dong Hoon Shin; Hyung-Sook Kim; Eunjeong Heo; Myoung-Jin Shin; Nak-Hyun Kim; Hyunju Lee; Jeong Su Park; Kyoung Un Park; Jongtak Jung; Kyoung-Ho Song; Minsun Kang; Jaehun Jung; Eu Suk Kim; Hong Bin Kim
Journal:  Microbiol Spectr       Date:  2022-04-25

4.  Clinical Outcomes with Ertapenem for Pneumonia in Obese versus Nonobese Patients.

Authors:  Ryan Caputo; Alan Rozycki; Megan McClain; M Mahdee Sobhanie; Kelci Coe; Nora Colburn; Lynn Wardlow
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

5.  Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.

Authors:  Pinyo Rattanaumpawan; Peerawong Werarak; Anupop Jitmuang; Pattarachai Kiratisin; Visanu Thamlikitkul
Journal:  BMC Infect Dis       Date:  2017-03-01       Impact factor: 3.090

6.  Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship.

Authors:  Young Kyung Yoon; Kyung Sook Yang; Seung Eun Lee; Hyun Jeong Kim; Jang Wook Sohn; Min Ja Kim
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

7.  Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review.

Authors:  Tiago Zequinão; João Paulo Telles; Juliano Gasparetto; Felipe Francisco Tuon
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-06       Impact factor: 1.581

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.